Skip Navigation

Center for Cancer Precision Medicine

  • The Center for Cancer Precision Medicine has merged with the Center for Cancer Genome Discovery. We are now the Center for Cancer Genomics.

    Learn more.

    In the Center for Cancer Precision Medicine (CCPM), our mission is to accelerate the development of "personalized" therapies that achieve long-term disease control and eventually cure many patients with advanced cancer.

    diagram of institutions affiliated with the Center for Cancer Precision Medicine

    CCPM brings together investigators and clinicians from Dana-Farber Cancer Institute (DFCI), Brigham and Women's Hospital (BWH), the Broad Institute of MIT and Harvard, and collaborating institutions to create a world-leading research enterprise dedicated to expanding the knowledge and technological foundation needed to implement precision cancer medicine.

    The CCPM faculty are engaged in research activities that address important questions in cancer precision medicine. The center is creating capabilities that can facilitate these collaborative projects with internal and external investigators. Through its research efforts, CCPM is interested in pushing the frontiers of biology, computational approaches, and laboratory efforts in precision medicine.

  • diagram of the Center for Cancer Precision Medicine process
  • An important goal of CCPM is to host a convening mechanism for identifying, vetting, prioritizing, and refining translational and clinical projects that provide outstanding opportunities for Dana-Farber/BWH/Broad investigators to make pivotal advances in the precision medicine arena. Such projects may include (but are not limited to) the following categories:

    • Using state-of-the-art and emerging technologies to identify cancer patients that benefit from new cancer drugs including conventional chemotherapy, targeted therapies, and immunotherapy
    • Determining which targeted drugs are achieving their desired effects inside the tumor cells
    • Defining the mechanisms by which cancers exhibit or develop resistance to therapies
    • Developing proof-of-concept, hypothesis-driven clinical studies of different therapeutics and combinations in conjunction with investigators from disease centers with appropriate correlative studies
    • Studying primary tumors and metastases to identify those patients whose tumors are likely to recur